Respiratory
Indacaterol
Brand: Onbrez®
PBAC's latest decision on Indacaterol: Recommended with restriction (2011). Considered for treatment of chronic obstructive pulmonary disease (COPD).
PBAC outcome
Recommended with restriction
Restricted benefit
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
2011 → 2011
Eligible population
patients with moderate-to-severe chronic obstructive pulmonary disease
- Therapy area
- Respiratory
- Line of therapy
- Later-line
- Evidence base
- RCT
- Primary endpoint
- FEV1 trough
- Key trials
- Study 2341, Study 2351, Aaron 2007, Cazzola 2007
- Comparator
- fluticasone with salmeterol
- Economic model
- Cost-minimisation
- Eligible patients/year
- 10,000
- ICER note
- Cost-minimisation analysis performed; no ICER calculated
Open on full dashboard →